Evidence map›Paper›PMID 38536576›Full record

ReviewCurrent hematologic malignancy reports2024

Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.

Reema K Tawfiq, Jithma P Abeykoon, Prashant Kapoor

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Reema K TawfiqDepartment of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Jithma P AbeykoonDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Prashant KapoorDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA. kapoor.prashant@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe treatment of Waldenström macroglobulinemia (WM) has evolved over the past decade. With the seminal discoveries of MYD88 and CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) mutations in WM cells, our understanding of the disease biology and treatment has improved. The development of a new class of agents, Bruton tyrosine kinase inhibitors (BTKi), has substantially impacted the treatment paradigm of WM. Herein, we review the current and emerging BTKi and the evidence for their use in WM. RECENT

findingsClinical trials have established the role of covalent BTKi in the treatment of WM. Their efficacy is compromised among patients who harbor CXCR4

Indexed as

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsWaldenstrom MacroglobulinemiaAntineoplastic Combined Chemotherapy ProtocolsDisease ManagementHumansMutationTreatment OutcomeAgammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein Kinase InhibitorsCXCR4 mutationIgM lymphoplasmacytic lymphomaLymphoproliferative disorderMonoclonal gammopathyMYD88 mutation

Identifiers

PMID38536576
OpenAlexW4393231871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.